To analyse the frequency of thromboembolic events when antipsychotics are administered, the results of 314 randomised, placebo-controlled clinical trials on serious adverse events observed in these trials were used. Overall, it can be said that thromboembolic events were rare in these trials, and that no significantly increased risk of these events was found when antipsychotics were given compared to placebo. There are indications of a possible increased risk when risperidone is administered and when older patients and patients with dementia are treated.
«
To analyse the frequency of thromboembolic events when antipsychotics are administered, the results of 314 randomised, placebo-controlled clinical trials on serious adverse events observed in these trials were used. Overall, it can be said that thromboembolic events were rare in these trials, and that no significantly increased risk of these events was found when antipsychotics were given compared to placebo. There are indications of a possible increased risk when risperidone is administered and...
»